We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
NEXOBRID (Nexo Pharmaceuticals Pty Ltd)
Product name
NEXOBRID
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
208 (255 working days)
Active ingredients
anacaulase-bcdb
Registration type
NCE/ NBE
Indication
The approved indications for this therapeutic good are:
- NEXOBRID is indicated for eschar removal in adults and paediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.
- For further information on acceptable burn types, see Section 4.4 Special Warnings and Precautions.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.